| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
GB:GSK
GlaxoSmithKline
|
Jun 17, 2026 | SELL |
Hold
-2.8% avg upside
25 analysts
|
$1800.00
6.50% Downside
|
· |
|
GB:AZN
AstraZeneca
|
Jun 10, 2026 | BUY |
Strong Buy
+12.2% avg upside
26 analysts
|
$16500.00
24.77% Upside
|
· |
|
CH:NOVN
Novartis AG
|
Jun 08, 2026 | HOLD |
Buy
-9.7% avg upside
30 analysts
|
$120.00
1.46% Upside
|
· |
|
GB:0QW0
arGEN X
|
May 28, 2026 | BUY |
Strong Buy
-22.9% avg upside
24 analysts
|
$900.00
16.94% Upside
|
· |
|
CH:ROP
Roche Holding AG
|
May 26, 2026 | BUY |
Buy
+3.2% avg upside
23 analysts
|
$410.00
28.13% Upside
|
· |
|
CH:GALD
Galderma Group AG
|
May 26, 2026 | BUY |
Strong Buy
+5.1% avg upside
10 analysts
|
$200.00
16.08% Upside
|
· |
|
GB:0MGB
Genmab A/S
|
May 22, 2026 | BUY |
Buy
+31.6% avg upside
22 analysts
|
$2500.00
52.32% Upside
|
· |
|
GB:0QIU
Novo Nordisk
|
May 19, 2026 | HOLD |
Hold
+40.1% avg upside
28 analysts
|
$300.00
2.19% Upside
|
· |
|
CH:SDZ
Sandoz Group Ltd
|
May 05, 2026 | BUY |
Buy
-5.8% avg upside
10 analysts
|
$75.00
10.34% Upside
|
· |
|
FR:SAN
Sanofi
|
Apr 23, 2026 | HOLD |
Strong Buy
+33.0% avg upside
30 analysts
|
$85.00
14.64% Upside
|
· |
|
GB:HIK
Hikma Pharmaceuticals
|
Mar 02, 2026 | SELL |
Buy
+64.2% avg upside
7 analysts
|
$1350.00
7.32% Downside
|
· |
|
NL:LKFT
Galapagos
|
Jan 23, 2025 | SELL |
Sell
+113.0% avg upside
16 analysts
|
$22.00
10.59% Downside
|
· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.